Start Time: 16:30 January 1, 0000 5:13 PM ET Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q4 2020 Earnings Conference Call February 10, 2021, 16:30 PM ET Company Participants Mihael Polymeropoulos - President and CEO Kevin Moran - SVP, CFO and Treasurer Conference Call Participants Chris Howerton - Jefferies Joel Beatty - Citi Operator Good afternoon, ladies and gentlemen, and welcome to the Q4 2020 Vanda Pharmaceuticals Inc. Earnings Conference Call. At this time, all participants are in a listen-only mode. La ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34186 VANDA PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 03-04918 ...

Call Start: 16:30 January 1, 0000 5:15 PM ET Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q3 2020 Earnings Conference Call October 28, 2020 04:30 PM ET Company Participants Mihael Polymeropoulos - President and Chief Executive Officer Kevin Moran - Senior Vice President and Chief Financial Officer Conference Call Participants Chris Howerton - Jefferies Joel Beatty - Citi Operator Ladies and gentlemen, thank you for standing by, and welcome to the Third Quarter 2020 Vanda Pharmaceuticals Earnings Conference Call ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Table of Contents VANDA PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 03-0491827 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the ...

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q2 2020 Earnings Conference Call August 5, 2020 4:30 PM ET Company Participants Mihael Polymeropoulos - President and Chief Executive Officer Kevin Moran - Senior Vice President and Chief Financial Officer Conference Call Participants Operator Welcome to the Q2 2020 Vanda Pharmaceuticals Inc. Earnings Conference Call. My name is Vanessa and I'll be the operator for today's call. At this time all participants are in a listen-only mode. Later we'll conduct a question-a ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34186 VANDA PHARMACEUTICALS INC. (State or other jurisdiction of incorporation or organization) Delaware 03-0 ...

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q1 2020 Earnings Conference Call May 6, 2020 4:30 PM ET Company Participants Mihael Polymeropoulos – Chief Executive Officer Kevin Moran – Acting-Chief Financial Officer Conference Call Participants Ben Porter – Stifel Operator Ladies and gentlemen, thank you for standing by, and welcome to the Q1 2020 Vanda Pharmaceuticals Inc. Earnings Conference Call. At this time all participants are in a listen-only mode. (Operator Instructions) I'd now like to hand the conferen ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 001-34186 VANDA PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 03-049 ...

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q4 2019 Earnings Conference Call February 25, 2020 4:30 PM ET Company Participants Mihales Polymeropoulos – President and Chief Executive Officer AJ Jones – Chief-Corporate Affairs Kevin Moran – Vice President and Controller Conference Call Participants Chris Howerton – Jefferies Shawn Egan – Citi Operator Ladies and gentlemen, thank you for standing by, and welcome to the Vanda Pharmaceuticals Fourth Quarter 2019 Earnings Conference Call. At this time, all participa ...

| --- | --- | --- | --- | --- | --- | |-------|-------|-------|-------|-------|--------------| | | | | | | | | | | | | | | | | | | | | | | | | | | | CORPORATE | | | | | | | | | | | | | | | | | | 2019 | | | | | | | | | | PRESENTATION | November 2019 Forward-Looking Statements Various statements in this presentation, including, but not limited to, Vanda's financial guidance for 2019, are "forward-looking statements" under the securities laws. Forward-looking statements are based upon current expectations that ...